Drugs / DCVax-L
DCVax-L
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00683241 | Nov 2007 → Dec 2009 | ovarian carcinoma, peritoneum cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07412197 | Aug 2026 → Dec 2029 expected | Lynch syndrome | Radboud University Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT01885702 | Oct 2010 → Apr 2016 | colorectal cancer | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03014804 | Dec 2019 → Dec 2020 | giant cell glioblastoma, gliosarcoma, oligodendroglioma | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT02285413 | Feb 2011 → Oct 2015 | melanoma | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00703105 | Oct 2008 → Jul 2021 | ovarian cancer | Loyola University | Unknown | No outcome recorded |
| Phase 2 | NCT00576537 | Mar 2001 → Oct 2011 | glioblastoma | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02146066 | — | glioblastoma | Northwest Biotherapeutics | Available | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00603460 Comparator | Jan 2012 → Jan 2013 | ovarian cancer, primary peritoneal carcinoma | University of Pennsylvania | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00045968 Comparator | Dec 2006 → Nov 2022 | brain cancer, glioblastoma | Northwest Biotherapeutics | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCVax-L | “Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment.” NCT00045968 ↗4“combination therapy using DCVax-L (Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen) and Nivolumab” NCT03014804 ↗ “After this, the blood and vaccine are mixed together to make the vaccine called DCVax-L.” NCT00683241 ↗ |
| Known as | DC vaccination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07412197 ↗ |
| Known as | Dendritic Cell Immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00576537 ↗ |
| Modality | Vaccine | “This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for newly diagnosed glioblastoma.” PMID 29843811 ↗ May 2018 |
| Route | Other | “into inguinal nodes identified by ultrasound guidance” NCT00703105 ↗ |